Blogger's Note: registration required to view (free)
open access
PracticeUpdate: Dr. Loprinzi, please speak about the current treatment regimens for chemotherapy-induced peripheral neuropathy.
Dr. Loprinzi: First, I’ll say a couple of words
about something that is obvious to many—chemotherapy-induced neuropathy
is a big, big problem; it is one of the more prominent toxicities we
have with a number of commonly used chemotherapy agents, such as the
platinum agents and taxanes.
Although chemotherapy-induced neuropathy will often get better for
many patients after stopping chemotherapy, it won’t for others and, for
some, it can become a chronic problem that lasts for years. Mostly,
we’re talking about peripheral neuropathy—stocking-and-glove numbness,
tingling, with or without pain; occasionally patients can also develop
some motor weakness.
We don’t have great ways of preventing the problem. Calcium and
magnesium for FOLFOX neuropathy has been most actively used in clinical
practice over the past decade; stay tuned for ASCO 2013, because a large
trial studying this issue will be presented there, which may set the
standard for whether or not this approach should continue to be used in
practice.
In terms of treatment of patients with established neuropathy, the
most common drugs used in clinical practice over the last decades have
been the gabapentinoids—gabapentin and pregabalin. Nonetheless, only one
reasonably sized, placebo-controlled, randomized controlled trial has
evaluated either of these drugs—that being gabapentin—and results were
convincingly negative.1 However, gabapentinoids are still
commonly used in clinical practice. It’s possible that the negative
results of the gabapentin trial were just by chance and that gabapentin
really does work (since it works for other neuropathy syndromes), or it
could be that gabapentin helps some patients and hurts others—
resulting, on average, with the trial showing no benefit. It is also
possible that pregabalin helps, but this has not been established by
clinical trials.........
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.